PF-4708671

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

35 publications

PF-4708671 Chemical Structure

CAS No. 1255517-76-0

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 107 In stock
USD 147 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PF-4708671 has been cited by 35 publications

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHVTWM2OD1yLkiyNFI1KM7:TR?= M4jMfHNCVkeHUh?=
UACC-893 NEPNPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe0flNEUUN3ME21MlE6QDh4IN88US=> MmLYV2FPT0WU
A427 NHviU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTTTWM2OD13LkeyOVY4KM7:TR?= MUHTRW5ITVJ?
OCUB-M M2C4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGixeVVKSzVyPU[uOlYyODJizszN M{LmWHNCVkeHUh?=
SW684 NWXEOFhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjtTWM2OD15LkWyNlY5KM7:TR?= NFqyUY1USU6JRWK=
SK-LMS-1 NWjkNJNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fJR2lEPTB;OT6wNVMxOiEQvF2= NHLETVJUSU6JRWK=
CP50-MEL-B M1LEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHnNJZKSzVyPUmuN|A1OTlizszN Mn\iV2FPT0WU
NCI-H1651 M3XReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz5TWM2OD1zMD6wNlc3KM7:TR?= Ml31V2FPT0WU
ABC-1 NUj2S5VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLkTWM2OD1zMD6xNFM4KM7:TR?= NH64XXVUSU6JRWK=
OE19 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFyLkG3N|Mh|ryP NF;FdHhUSU6JRWK=
DSH1 M3TIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X5cWlEPTB;MUCuPFg4QSEQvF2= NGr5PFVUSU6JRWK=
SW13 M{nPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFzLkmzNVkh|ryP MkfqV2FPT0WU
MDA-MB-453 NYruO|ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG0TWM2OD1zMj6xOlA{KM7:TR?= MlexV2FPT0WU
647-V MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW4TWM2OD1zMj6zOVgzKM7:TR?= Mly1V2FPT0WU
NCI-H2342 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLsRplxUUN3ME2xNk4{QTl3IN88US=> NH7FNJlUSU6JRWK=
LB2241-RCC NX\z[FdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XuemlEPTB;MUKuOVc4QSEQvF2= NV7q[HFUW0GQR1XS
UACC-257 NFnsZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHvTWM2OD1zMz60OFU{KM7:TR?= NIPySldUSU6JRWK=
NCI-H661 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPNTWM2OD1zMz62OFQ6KM7:TR?= MXPTRW5ITVJ?
FADU MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLWTWM2OD1zMz62PVkzKM7:TR?= M13TVnNCVkeHUh?=
A2780 NGnqeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSwcmlKUUN3ME2xN{45ODRzIN88US=> NIC3b4VUSU6JRWK=
NCI-H1793 M1T3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:1OlBKSzVyPUG0MlQxQDVizszN MoruV2FPT0WU
TE-8 M1zEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPVboZvUUN3ME2xOU4{PDZ3IN88US=> NHjxO4FUSU6JRWK=
HGC-27 NWTkWIplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF4LkG2OFQh|ryP NGnSW2ZUSU6JRWK=
MMAC-SF MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H2OWlEPTB;MUeuN|czPyEQvF2= NX;NSItYW0GQR1XS
Calu-6 NHTLbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHzSnlnUUN3ME2xPE4yPTF|IN88US=> M1zjUXNCVkeHUh?=
HUTU-80 M{XzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF6LkO5OVkh|ryP MVfTRW5ITVJ?
SAS NHvo[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLZSFNKSzVyPUG4MlY1PTVizszN NG\LOGFUSU6JRWK=
IST-MES1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInDW3JKSzVyPUG4MlY2ODhizszN NIe3TW1USU6JRWK=
C3A NXv0bIZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXOb|ZvUUN3ME2xPE44QTF7IN88US=> M1XpNXNCVkeHUh?=
ES3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjNTWM2OD1zOD64N|Y1KM7:TR?= MkPMV2FPT0WU
HSC-2 NVK5TIlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LVV2lEPTB;MUmuOlU1OSEQvF2= MYPTRW5ITVJ?
T47D MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfGXY9KSzVyPUKwMlE1QDVizszN MXrTRW5ITVJ?
EW-7 NFu3fpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{THWmlEPTB;MkCuPFU5QCEQvF2= NUHrR3JQW0GQR1XS
LN-405 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LhcWlEPTB;MkCuPFk3PSEQvF2= M1q5eHNCVkeHUh?=
U031 NETHfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j3OmlEPTB;MkGuOFgxOiEQvF2= NEnKbYpUSU6JRWK=
A549 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq4TWM2OD1{MT64OFkyKM7:TR?= NXfUe45HW0GQR1XS
RMG-I Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ{LkK2Olgh|ryP Ml\YV2FPT0WU
BT-474 NY\LXW5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnmPJZxUUN3ME2yNk43PTVzIN88US=> NWnSbGxVW0GQR1XS
NB69 Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ|LkG1NkDPxE1? NXrqVYQ5W0GQR1XS
NB7 M2rGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnxdm1jUUN3ME2yOE4yQDhizszN M160U3NCVkeHUh?=
HCC1569 NV3ueJA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu2TWM2OD1{ND62NVI2KM7:TR?= MXzTRW5ITVJ?
MEL-JUSO MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqzTWM2OD1{ND62PVA5KM7:TR?= NETndmdUSU6JRWK=
MDA-MB-175-VII MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T6WWlEPTB;MkWuNlUyPyEQvF2= MVzTRW5ITVJ?
HCC1419 M3HVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fuU2lEPTB;MkWuOlAxOyEQvF2= M2rHVHNCVkeHUh?=
Ca9-22 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL5WnhIUUN3ME2yOU43PDN{IN88US=> Mm\rV2FPT0WU
KGN M4XHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKyVJlpUUN3ME2yOU44PTR5IN88US=> MW\TRW5ITVJ?
LB373-MEL-D MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJ4LkG5N|gh|ryP MX\TRW5ITVJ?
NCI-H1755 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ4Lki4OFEh|ryP NWDFW4luW0GQR1XS
D-423MG NHfh[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XLTWlEPTB;MkeuNFcyPSEQvF2= MoG1V2FPT0WU
DK-MG MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJ6Lke4OFYh|ryP NX:2XGJQW0GQR1XS
NCI-H1623 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET1RllKSzVyPUK4Mlg{PDJizszN M{XPeXNCVkeHUh?=
KU-19-19 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPoUW1[UUN3ME2yPE46QTVizszN M1PvdXNCVkeHUh?=
C-33-A MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ7LkKxPVgh|ryP MmjhV2FPT0WU
SCC-4 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHlXml2UUN3ME2zNE4{OzV2IN88US=> NHz2ZZJUSU6JRWK=
MG-63 MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTNyLkW5PVQh|ryP MXTTRW5ITVJ?
LNCaP-Clone-FGC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HBTGlEPTB;M{GuOFkzOSEQvF2= MVrTRW5ITVJ?
CAPAN-1 NUjweXFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTNzLkWyPFYh|ryP MUTTRW5ITVJ?
GI-ME-N NFzxOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jvTWlEPTB;M{GuOVM2OyEQvF2= MVzTRW5ITVJ?
RERF-LC-MS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe3UII3UUN3ME2zNk43PzR5IN88US=> M1vHPXNCVkeHUh?=
KLE MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPoTWM2OD1|Mz60N|M1KM7:TR?= M4\HUXNCVkeHUh?=
KNS-81-FD NFzUfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN|LkWwNFgh|ryP NHrHRlFUSU6JRWK=
DOK Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy2cpNKSzVyPUO0MlY3OTJizszN NHPCdGNUSU6JRWK=
ACHN Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nwW2lEPTB;M{WuNVU5QCEQvF2= M4r5c3NCVkeHUh?=
KYSE-520 M3v5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LYUmlEPTB;M{WuNlM3OSEQvF2= NETyXWVUSU6JRWK=
SBC-5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKxTWM2OD1|NT61NVE3KM7:TR?= NICyfYpUSU6JRWK=
NCI-H28 NUPtVXpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTN3Lk[2PVUh|ryP MoPqV2FPT0WU
ES7 NVnFUXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jPTWlEPTB;M{[uNlI1QSEQvF2= MYTTRW5ITVJ?
A172 M{jTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T3N2lEPTB;M{[uOFE5PyEQvF2= MkfHV2FPT0WU
UM-UC-3 NGDUW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PnO2lEPTB;M{euPFc1PiEQvF2= MWjTRW5ITVJ?
LXF-289 NFXRUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL6eIJKSzVyPUO4MlAxPDdizszN NVPNUIE6W0GQR1XS
KP-4 NFzOTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\x[2ZoUUN3ME2zPE41PzN7IN88US=> MoPhV2FPT0WU
TE-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTKTWM2OD1|OT62OVg6KM7:TR?= NUXQZ5F2W0GQR1XS
G-402 Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHruV4FKSzVyPUSwMlA3OSEQvF2= NF[4RoNUSU6JRWK=
786-0 M1K4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTRyLkmwPVYh|ryP Mn62V2FPT0WU
K5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrkbJRJUUN3ME20NU4{Pjh4IN88US=> NHL4bolUSU6JRWK=
SK-N-DZ MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P6d2lEPTB;NEGuN|gzOyEQvF2= MYnTRW5ITVJ?
OVCAR-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XWT2lEPTB;NEGuO|U3QCEQvF2= MVvTRW5ITVJ?
T84 M1;QdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DPNmlEPTB;NEKuNVI3OyEQvF2= M4jKdnNCVkeHUh?=
GCIY MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HzTWlEPTB;NEOuNFgxOyEQvF2= Mn7mV2FPT0WU
BB49-HNC MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfGcFhKSzVyPUSzMlM{PDhizszN MUfTRW5ITVJ?
SNU-C2B MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HyemlEPTB;NEOuOlQ{PiEQvF2= NVfW[2F6W0GQR1XS
TE-6 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq4[ZBKSzVyPUSzMlg5QTRizszN NX\OPZNbW0GQR1XS
23132-87 NUX3W5pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTR2LkK5O|gh|ryP MXHTRW5ITVJ?
DMS-53 MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTR2LkOzPFQh|ryP NEXJUY1USU6JRWK=
ONS-76 MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmxUZFKSzVyPUS0Mlc3PjFizszN MUDTRW5ITVJ?
DMS-273 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTR2Lkm0N{DPxE1? M3XL[XNCVkeHUh?=
COLO-824 NIPxZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[2XmlEPTB;NEWuPFc4PSEQvF2= M3HETnNCVkeHUh?=
DMS-114 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTR3Lki5Nlch|ryP MXXTRW5ITVJ?
YKG-1 NV;Ke2NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW1TWM2OD12Nj6wN|U2KM7:TR?= MWDTRW5ITVJ?
RH-18 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXJVW9KSzVyPUS2MlM4OzNizszN NXfadFFrW0GQR1XS
NCI-H1355 NYnrb4RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHTWmZmUUN3ME20Ok43OThizszN M3vOfXNCVkeHUh?=
NCI-H2170 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS5VYhMUUN3ME20O{44PTh2IN88US=> MX3TRW5ITVJ?
OC-314 NEDZToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorpTWM2OD12Nz64OFc5KM7:TR?= NVjDWFhmW0GQR1XS
NCI-H2030 M{nk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvZc2NKSzVyPUS3Mlg6ODZizszN MX7TRW5ITVJ?
22RV1 NIjseopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW4VXltUUN3ME20O{46ODF3IN88US=> Mm\iV2FPT0WU
G-401 NFLERYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLCTWM2OD12OD60OFE2KM7:TR?= MmTrV2FPT0WU
YAPC MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS4W2lSUUN3ME20PU45ODd|IN88US=> M3jKe3NCVkeHUh?=
SW1573 MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;5PWlEPTB;NUCuNlQ{PSEQvF2= MWHTRW5ITVJ?
COLO-792 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTVyLk[yN|ch|ryP MVPTRW5ITVJ?
KNS-62 NUTCSZRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\HcWVKSzVyPUWwMlc2ODhizszN NV[5SGxvW0GQR1XS
NB5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfFfWRiUUN3ME21NU41PTB7IN88US=> NEPDdnpUSU6JRWK=
CP66-MEL Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PMbWlEPTB;NUGuOlQxQCEQvF2= Mo\WV2FPT0WU
CaR-1 NEDDfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXNbWNKSzVyPUWyMlA3ODZizszN NFTBTFBUSU6JRWK=
CAL-54 NX;2R4I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P2NGlEPTB;NUKuNVExOiEQvF2= MlfHV2FPT0WU
8305C NGnnXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTV{LkOxOUDPxE1? NXXJXVNWW0GQR1XS
Calu-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTV{LkO3N|Mh|ryP MniwV2FPT0WU
AU565 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jybmlEPTB;NUKuOVUxQSEQvF2= Mof0V2FPT0WU
CW-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DQZ2lEPTB;NUKuPFY2PCEQvF2= MVLTRW5ITVJ?
BEN MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe2Z45KSzVyPUWzMlc5PjJizszN MljaV2FPT0WU
NCI-H1975 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13kVGlEPTB;NUOuPFk3PiEQvF2= NXvaTGo4W0GQR1XS
HCT-116 NIDy[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLIc3k4UUN3ME21OE4xOzJ5IN88US=> M{nvUXNCVkeHUh?=
SH-4 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC3XHdKSzVyPUW0MlE{QCEQvF2= NWDwWXFvW0GQR1XS
NCI-H1693 M17YXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTV2LkKxNFMh|ryP MoDSV2FPT0WU
BPH-1 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTCbpR7UUN3ME21OU4zQDl{IN88US=> MorJV2FPT0WU
CAMA-1 NWDlfZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL6d|dKSzVyPUW1MlgyOTZizszN MlzCV2FPT0WU
A388 M3zPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDGTWM2OD13Nj6wPVg2KM7:TR?= NYfGVWw6W0GQR1XS
C2BBe1 M4LYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfiTWM2OD13Nj6yOlM1KM7:TR?= MmjsV2FPT0WU
GAMG MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTV4LkW5OVUh|ryP MkPyV2FPT0WU
MKN28 NVrQSWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPNd2NKSzVyPUW2MlgxOTNizszN NWrXeIVUW0GQR1XS
VA-ES-BJ NWjuSlZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PJ[WlEPTB;NU[uPFc1PSEQvF2= M2XjcXNCVkeHUh?=
HuCCT1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHHNGZvUUN3ME21O{4xPDl{IN88US=> MX7TRW5ITVJ?
BFTC-905 NGLsW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nJRmlEPTB;NUeuNlg6QCEQvF2= NEjTO5BUSU6JRWK=
LS-123 M13rcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTXTWM2OD13Nz61OlY5KM7:TR?= NEXCT41USU6JRWK=
LB996-RCC NHnVWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK3SlNTUUN3ME21PE4xOjh5IN88US=> MmryV2FPT0WU
NCI-H1048 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PQUGlEPTB;NUiuNlE5QCEQvF2= NFnz[GxUSU6JRWK=
COR-L105 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXsOIhKSzVyPUW4Mlc{OzdizszN NYrH[I5wW0GQR1XS
OVCAR-8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPyTWM2OD13OT6xO|E3KM7:TR?= M1O0WXNCVkeHUh?=
SK-N-FI MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfjZ4ZpUUN3ME21PU4{OjB5IN88US=> NVSxdllEW0GQR1XS
MES-SA MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS4TWM2OD13OT60OVA6KM7:TR?= NXzqb4NxW0GQR1XS
SCC-9 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW2WHFKSzVyPUW5MlQ4PTNizszN NXzsS4F4W0GQR1XS
EFO-27 NWPFOll1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHodJhMUUN3ME21PU46PDNizszN MXrTRW5ITVJ?
GT3TKB NUHEZYRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HOSGlEPTB;NkCuOlA1QCEQvF2= MWDTRW5ITVJ?
HCC38 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[xO2lEPTB;NkGuOFM4QSEQvF2= NEXhXZdUSU6JRWK=
MLMA NEfs[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTZzLk[xOlMh|ryP M2DmdXNCVkeHUh?=
D-566MG NGrycVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTZ|LkWyNlQh|ryP NEPzZpBUSU6JRWK=
SF295 MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzhTWM2OD14Mz62OlU2KM7:TR?= NVPhUoc1W0GQR1XS
ES4 NGP2cnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;BdphTUUN3ME22OE41PzF7IN88US=> NIOxbmdUSU6JRWK=
CAKI-1 NIDxUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P6d2lEPTB;NkSuOVczOSEQvF2= NV;ieItEW0GQR1XS
OAW-28 NE\3[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXxV5c1UUN3ME22OE46PjR5IN88US=> NUfDVplSW0GQR1XS
NCI-H460 NUHPU29VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHGTFE2UUN3ME22OU4xQDl5IN88US=> MmGxV2FPT0WU
JAR NGT0Zm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLifYp2UUN3ME22OU42PTF4IN88US=> M3voWHNCVkeHUh?=
SNU-449 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTZ3Lke2NVYh|ryP MljYV2FPT0WU
D-392MG M3za[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfrTWM2OD14NT65OFM1KM7:TR?= NHXncoxUSU6JRWK=
EW-22 NYT3OHp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLUc3VKSzVyPU[2MlM6PSEQvF2= NV6xPYZRW0GQR1XS
GCT M3KyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r5Z2lEPTB;NkeuNFQ1OyEQvF2= MVfTRW5ITVJ?
NOS-1 M{i4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD3TWM2OD14Nz62PFY4KM7:TR?= MULTRW5ITVJ?
RH-1 MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrMTWM2OD14OD61OVU6KM7:TR?= M4PFU3NCVkeHUh?=
HuH-7 NG\lWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLabphNUUN3ME22PU4yODB{IN88US=> NVvHOYZbW0GQR1XS
NUGC-3 NYL3cXYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTdyLkm2OFQh|ryP M4njPXNCVkeHUh?=
IST-SL1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qy[mlEPTB;N{GuNlMzPCEQvF2= MkDRV2FPT0WU
SHP-77 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrCU|ZVUUN3ME23Nk4yOTlizszN MYDTRW5ITVJ?
SW1116 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:ycmlEPTB;N{KuNVQxPyEQvF2= NX25N5VEW0GQR1XS
LK-2 NEjTdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\zTWM2OD15Mj64OlEzKM7:TR?= MV;TRW5ITVJ?
U-2-OS M{Tqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjuU|hqUUN3ME23N{4yQDJ6IN88US=> Mm[3V2FPT0WU
KYSE-150 NU\zeXkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm0TWM2OD15Mz62NVE5KM7:TR?= NVS2NIdbW0GQR1XS
U251 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC0TWM2OD15Mz64NVY5KM7:TR?= NYnhN4dCW0GQR1XS
HT-1080 M3:2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfsd2s3UUN3ME23OE4zPTd2IN88US=> NWS0NY5EW0GQR1XS
NCI-H1437 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XNRWlEPTB;N{SuOlMzPiEQvF2= MlLiV2FPT0WU
HPAF-II M{TGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfNTHI1UUN3ME23OE43PDF3IN88US=> MkXWV2FPT0WU
Becker NVLlVHlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rMZ2lEPTB;N{WuNVExPSEQvF2= MULTRW5ITVJ?
PANC-10-05 NIKwdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTd3LkK4OlUh|ryP MXHTRW5ITVJ?
TYK-nu MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7UTWM2OD15NT6zNVAzKM7:TR?= M1nqNXNCVkeHUh?=
SKG-IIIa M2rzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLMSXpsUUN3ME23OU4{OzRzIN88US=> MmnlV2FPT0WU
NCI-H1993 NGT0S3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\Y[XFuUUN3ME23OU44Ozl5IN88US=> MV3TRW5ITVJ?
S-117 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HWV2lEPTB;N{WuO|U2KM7:TR?= M3\vN3NCVkeHUh?=
HuO9 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK5V4JKSzVyPUe2MlAxPDhizszN NXm5N2Y1W0GQR1XS
CAL-51 NFvYXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq3b3dKSzVyPUe2MlExODZizszN M3TaVnNCVkeHUh?=
BT-20 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[5[GlEPTB;N{[uNlE3QCEQvF2= NIfPZ3FUSU6JRWK=
LB831-BLC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK1U4FKSzVyPUe2MlMzOTdizszN NITTNZhUSU6JRWK=
LB1047-RCC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\VbWlEPTB;N{[uO|YyQSEQvF2= NFfIOpFUSU6JRWK=
ES8 NXLLVXI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1GxWmlEPTB;N{iuNFA4OyEQvF2= MYTTRW5ITVJ?
UMC-11 M1LVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DrcWlEPTB;N{iuNFg5PCEQvF2= MX7TRW5ITVJ?
NCI-H226 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW5NHhJUUN3ME23PE4yOzF3IN88US=> M3XVeXNCVkeHUh?=
IGROV-1 NGqxfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTd6LkW1OUDPxE1? MWnTRW5ITVJ?
BHY NFHLV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKxU5p{UUN3ME23PU42QTZizszN M3XzN3NCVkeHUh?=
MKN45 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRThyLkOxO|Qh|ryP M{DrPHNCVkeHUh?=
IA-LM M3TBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17BbWlEPTB;OECuN|UyOSEQvF2= MnXOV2FPT0WU
WM-115 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rleGlEPTB;OEGuOFEyPCEQvF2= MX;TRW5ITVJ?
VMRC-RCZ NHvYWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\NdVlpUUN3ME24NU41PDJ3IN88US=> NVnETmV5W0GQR1XS
NCI-H2291 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljoTWM2OD16MT62PFQzKM7:TR?= M4X1fXNCVkeHUh?=
MCF7 Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTh|LkK4PVch|ryP M3nDZnNCVkeHUh?=
639-V NGS5T4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfublBKSzVyPUi0MlYyOjlizszN Mk\yV2FPT0WU
RT4 NInPWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m0RWlEPTB;OEWuNlQxOyEQvF2= MkHqV2FPT0WU
NCI-H2405 Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLJRllIUUN3ME24OU4zQTl5IN88US=> NYPLRoZqW0GQR1XS
CAL-33 M3TLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTh3Lk[zNVUh|ryP Mmn1V2FPT0WU
BT-549 Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTh3LkmzPFIh|ryP NIniRplUSU6JRWK=
HT-1197 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF72WI1KSzVyPUi4MlExPzdizszN MoK5V2FPT0WU
G-361 NVvWNWJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTh6LkG0O|Qh|ryP M3jQXXNCVkeHUh?=
LS-411N NUT2[JFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\RTWM2OD16OT6zN|g5KM7:TR?= M3vUZnNCVkeHUh?=
HT-144 NHnIRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTh7LkW5PVIh|ryP Moj2V2FPT0WU
DJM-1 M4LOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX3clZFUUN3ME24PU45QDR3IN88US=> NFfDXnRUSU6JRWK=
CAL-12T NIrkeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfoOXl4UUN3ME25NE44QDl3IN88US=> MWjTRW5ITVJ?
MKN7 MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDCZXVUUUN3ME25NU4{PTVzIN88US=> NGrzNJhUSU6JRWK=
HuP-T3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnj[WlxUUN3ME25Ok4yODB2IN88US=> MUnTRW5ITVJ?
SK-MG-1 NWfXbVFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rNO2lEPTB;OU[uNVM1QCEQvF2= M{G3UHNCVkeHUh?=
NCI-H2347 M4GzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnYVIVKSzVyPUm4MlExPDJizszN MXjTRW5ITVJ?
SW872 M4nvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHVTWM2OD1zMECuOFU3KM7:TR?= MlizV2FPT0WU
COLO-829 NYHMPHd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq1WJVKSzVyPUGwNE42PTNizszN NHTJZ4FUSU6JRWK=
MC-IXC NYrKbY16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPU[mhkUUN3ME2xNFAvPjF3IN88US=> MmTxV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

30423811 28626016
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A
Smiles CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID